Morepen Labs.

Morepen Laboratories Ltd Balance Sheet

NSEBSE

₹60.17

(-3.93%)

Apr 30, 2025|03:59:10 PM

Invest wise with Expert advice

QUICKLINKS FOR Morepen Laboratories Ltd

FINANCIALS

Profit & Loss Balance Sheet Cash Flow Ratios Results

ConsolidatedStandalone

GraphTable

Y/e 31 Mar( In .Cr)	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Equity Capital	102.23	102.23	121.81	133.71
Preference Capital	0	0	0	0
Reserves	786.8	677.89	476.36	311.26
Net Worth	889.03	780.12	598.17	444.97
Minority Interest
Debt	28.19	25.16	18.57	17.05
Deferred Tax Liability Net	12.63	12.26	11.67	0
Total Liabilities	929.85	817.54	628.41	462.02
Fixed Assets	240.99	187.83	170.26	145.98
Intangible Assets
Investments	126.18	117.84	117.79	118.78
Deferred Tax Asset Net	10.38	9.57	9.18	0
Networking Capital	501.83	446.39	285.62	130.28
Inventories	220.15	211.35	258.25	169.61
Inventory Days				55.65
Sundry Debtors	316.89	255.47	221.87	155.52
Debtor Days				51.02
Other Current Assets	324.63	277.14	219.54	190.63
Sundry Creditors	-267.43	-213.1	-217.32	-192.33
Creditor Days				63.1
Other Current Liabilities	-92.41	-84.47	-196.72	-193.15
Cash	50.48	55.9	45.55	66.98
Total Assets	929.86	817.53	628.4	462.02

Morepen Labs. : related Articles

Morepen Labs Secures China’s NMPA Approval for Loratadine Export

1 Apr 2025|02:22 PM

With this approval, Morepen Laboratories aims to strengthen its presence in China, which is one of the world’s largest pharmaceutical markets.

Morepen Launches Empamore for Diabetes, Heart & Kidney Care

18 Mar 2025|01:30 PM

Developed from scratch, this drug offers an inexpensive and superior alternative to current treatments, making it accessible to hundreds of millions of patients.